Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy

Maged Costantine, Ilan Matok, Giuseppe Chiossi, Shannon Clark, Menachem Miodovnik, Jason G. Umans, Steve Caritis, Gary Hankins, Gideon Koren

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVE: Women often hesitate to take medications in pregnancy due to fears of perceived potential fetal damage. The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP). METHODS: The authors performed a prespecified secondary analysis of a multicenter double-blind randomized controlled trial of Diclectin versus placebo for the treatment of NVP. Data on adherence to study medication were collected in all patients. The primary outcome of this analysis was adherence to study medication, which was determined by pill counting and patient diaries. The treatment regimen in the original trial was not fixed and depended on patient's symptoms. There was no difference in the adherence rates between subjects in the Diclectin or placebo arms of the study, so the 2 arms were analyzed as one cohort. The degree of adherence was analyzed in the various subgroups. Subsequently, a multiple linear regression model was constructed to identify predictors to adherence. RESULTS: Two hundred fifty-eight women were included in this analysis. There were no differences in adherence rates according to ethnicity, race, or the presence of adverse events. Gravidity, average number of prescribed tablets per day, site of enrollment, and change in NVP severity measured by the pregnancy unique-quantification of emesis score were associated with adherence. In multivariable analysis, average number of tablets per day, change in pregnancy unique-quantification of emesis, number of treatment days, site of enrollment were significantly predictive of adherence, with the former being negatively correlated. CONCLUSION: Adherence to antinauseants for NVP is affected by number of tablets prescribed per day, and treatment duration and effectiveness.

Original languageEnglish (US)
Pages (from-to)569-573
Number of pages5
JournalTherapeutic Drug Monitoring
Volume34
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

Doxylamine
Pyridoxine
Nausea
Vomiting
Pregnancy
Tablets
Linear Models
Placebos
Gravidity
Fear
Therapeutics
Randomized Controlled Trials

Keywords

  • adherence
  • doxylamine
  • nausea and vomiting of pregnancy
  • pyridoxine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. / Costantine, Maged; Matok, Ilan; Chiossi, Giuseppe; Clark, Shannon; Miodovnik, Menachem; Umans, Jason G.; Caritis, Steve; Hankins, Gary; Koren, Gideon.

In: Therapeutic Drug Monitoring, Vol. 34, No. 5, 10.2012, p. 569-573.

Research output: Contribution to journalArticle

Costantine, M, Matok, I, Chiossi, G, Clark, S, Miodovnik, M, Umans, JG, Caritis, S, Hankins, G & Koren, G 2012, 'Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy', Therapeutic Drug Monitoring, vol. 34, no. 5, pp. 569-573. https://doi.org/10.1097/FTD.0b013e31826e7997
Costantine, Maged ; Matok, Ilan ; Chiossi, Giuseppe ; Clark, Shannon ; Miodovnik, Menachem ; Umans, Jason G. ; Caritis, Steve ; Hankins, Gary ; Koren, Gideon. / Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. In: Therapeutic Drug Monitoring. 2012 ; Vol. 34, No. 5. pp. 569-573.
@article{f80a80ad239e4e78b1f4361ebb2e414e,
title = "Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy",
abstract = "OBJECTIVE: Women often hesitate to take medications in pregnancy due to fears of perceived potential fetal damage. The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP). METHODS: The authors performed a prespecified secondary analysis of a multicenter double-blind randomized controlled trial of Diclectin versus placebo for the treatment of NVP. Data on adherence to study medication were collected in all patients. The primary outcome of this analysis was adherence to study medication, which was determined by pill counting and patient diaries. The treatment regimen in the original trial was not fixed and depended on patient's symptoms. There was no difference in the adherence rates between subjects in the Diclectin or placebo arms of the study, so the 2 arms were analyzed as one cohort. The degree of adherence was analyzed in the various subgroups. Subsequently, a multiple linear regression model was constructed to identify predictors to adherence. RESULTS: Two hundred fifty-eight women were included in this analysis. There were no differences in adherence rates according to ethnicity, race, or the presence of adverse events. Gravidity, average number of prescribed tablets per day, site of enrollment, and change in NVP severity measured by the pregnancy unique-quantification of emesis score were associated with adherence. In multivariable analysis, average number of tablets per day, change in pregnancy unique-quantification of emesis, number of treatment days, site of enrollment were significantly predictive of adherence, with the former being negatively correlated. CONCLUSION: Adherence to antinauseants for NVP is affected by number of tablets prescribed per day, and treatment duration and effectiveness.",
keywords = "adherence, doxylamine, nausea and vomiting of pregnancy, pyridoxine",
author = "Maged Costantine and Ilan Matok and Giuseppe Chiossi and Shannon Clark and Menachem Miodovnik and Umans, {Jason G.} and Steve Caritis and Gary Hankins and Gideon Koren",
year = "2012",
month = "10",
doi = "10.1097/FTD.0b013e31826e7997",
language = "English (US)",
volume = "34",
pages = "569--573",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy

AU - Costantine, Maged

AU - Matok, Ilan

AU - Chiossi, Giuseppe

AU - Clark, Shannon

AU - Miodovnik, Menachem

AU - Umans, Jason G.

AU - Caritis, Steve

AU - Hankins, Gary

AU - Koren, Gideon

PY - 2012/10

Y1 - 2012/10

N2 - OBJECTIVE: Women often hesitate to take medications in pregnancy due to fears of perceived potential fetal damage. The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP). METHODS: The authors performed a prespecified secondary analysis of a multicenter double-blind randomized controlled trial of Diclectin versus placebo for the treatment of NVP. Data on adherence to study medication were collected in all patients. The primary outcome of this analysis was adherence to study medication, which was determined by pill counting and patient diaries. The treatment regimen in the original trial was not fixed and depended on patient's symptoms. There was no difference in the adherence rates between subjects in the Diclectin or placebo arms of the study, so the 2 arms were analyzed as one cohort. The degree of adherence was analyzed in the various subgroups. Subsequently, a multiple linear regression model was constructed to identify predictors to adherence. RESULTS: Two hundred fifty-eight women were included in this analysis. There were no differences in adherence rates according to ethnicity, race, or the presence of adverse events. Gravidity, average number of prescribed tablets per day, site of enrollment, and change in NVP severity measured by the pregnancy unique-quantification of emesis score were associated with adherence. In multivariable analysis, average number of tablets per day, change in pregnancy unique-quantification of emesis, number of treatment days, site of enrollment were significantly predictive of adherence, with the former being negatively correlated. CONCLUSION: Adherence to antinauseants for NVP is affected by number of tablets prescribed per day, and treatment duration and effectiveness.

AB - OBJECTIVE: Women often hesitate to take medications in pregnancy due to fears of perceived potential fetal damage. The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP). METHODS: The authors performed a prespecified secondary analysis of a multicenter double-blind randomized controlled trial of Diclectin versus placebo for the treatment of NVP. Data on adherence to study medication were collected in all patients. The primary outcome of this analysis was adherence to study medication, which was determined by pill counting and patient diaries. The treatment regimen in the original trial was not fixed and depended on patient's symptoms. There was no difference in the adherence rates between subjects in the Diclectin or placebo arms of the study, so the 2 arms were analyzed as one cohort. The degree of adherence was analyzed in the various subgroups. Subsequently, a multiple linear regression model was constructed to identify predictors to adherence. RESULTS: Two hundred fifty-eight women were included in this analysis. There were no differences in adherence rates according to ethnicity, race, or the presence of adverse events. Gravidity, average number of prescribed tablets per day, site of enrollment, and change in NVP severity measured by the pregnancy unique-quantification of emesis score were associated with adherence. In multivariable analysis, average number of tablets per day, change in pregnancy unique-quantification of emesis, number of treatment days, site of enrollment were significantly predictive of adherence, with the former being negatively correlated. CONCLUSION: Adherence to antinauseants for NVP is affected by number of tablets prescribed per day, and treatment duration and effectiveness.

KW - adherence

KW - doxylamine

KW - nausea and vomiting of pregnancy

KW - pyridoxine

UR - http://www.scopus.com/inward/record.url?scp=84866548310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866548310&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e31826e7997

DO - 10.1097/FTD.0b013e31826e7997

M3 - Article

C2 - 22972538

AN - SCOPUS:84866548310

VL - 34

SP - 569

EP - 573

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 5

ER -